SUMMARY A consecutive series of 489 patients with rheumatoid arthritis seen at the centre was studied to determine their cancer morbidity. Overall the 36 cancers diagnosed in the series between 1964 and 1981 were not significantly in excess of the expected number, but there was a highly significant excess of tumours of the reticuloendothelial system. The excess was mainly due to 6 observed cases of lymphoma. We conclude that there is a highly significant association between rheumatoid arthritis and the subsequent development of lymphoproliferative malignancy in this
series.
An increased incidence of lymphoproliferative malignancy (LPM) has been suggested to occur in various connective tissue diseases. These include Sjogren's syndrome' 2 rheumatoid arthritis (RA),3-à nd systemic lupus erythematosus.6 ' RA is the commonest of these diseases and has been the focus of attention. However, the evidence that the risk of malignancy is increased in RA is conflicting. One large Scandinavian series5 has reported a highly significant association (relative risk = 2 2) between RA (8 4%) . Age-distribution by sex for the 448 patients included in the analysis are shown in Table 1 . 26% of the patients were seen in hospital before 40 years of age. Rheumatoid factor status was known for 421 patients (94%), of whom 252 (60%) were seropositive. A complete drug history was not available for every patient. However, the use of gold and steroids was known for 424 and 438 patients respectively. Among these patients 36% had received gold, 51 8 % steroids, and 25 % had neither. In terms of the total series (448 patients) 50 7% received steroids and 34-2% gold. The other frequently used secondline drugs were chloroquine (7 8%) and penicillamine (6-3%). Dapsone was used in 7 cases, sulphasalazine (Salazopyrin) in 5 cases, and azathioprine in 2 cases. Single drug therapy was recorded for 37*4% patients, and the use of combination or multiple sequental drugs was known for 32 6 % of patients. Analgesics and aspirin (and 'aspirin-like' drugs) were given to almost all patients, and the extent of their prescription in general practice is unknown.
Overall the 36 cancers diagnosed in the series within the period of review were not significantly in excess of the expected number ( Table 2 ). The observed and expected numbers for individual sites have been grouped by main anatomical systems according to categories of the International Classification of Disease (8th revision). Only for cancers of the reticuloendothelial system was the observed number significantly in excess of the expected number (p<0-001). No other significant deviation from expectation was observed, and, when cancers other than those of the RES were combined, the observed and expected number corresponded very closely ( Table 3 ). The highly significant excess of RES cancers (relative risk = 8 0; 95% confidence limits: 3-7 to 15-2) was apparent in both men and (Table 5 ).
When all 6 observed cases of lymphoma were included in the analysis a very high relative risk was found in the first 5 years after first attendance (Table  6 ). Thereafter the cumulative relative risk was of the order of 25-fold. On excluding the 2 cases in the first year the cumulative risk increased over time. For other RES tumours combined the cumulative risk was comparatively constant over time. The difficulty of relating interval from date first seen with onset is shown in Table 7 , where the 6 cases of lymphoma are arranged by increasing interval from onset. The 2 lymphosarcomas, diagnosed within one year of first group.bmj.com on August 28, 2017 -Published by http://ard.bmj.com/ Downloaded from attendance, showed only a short interval from onset, whereas those with the longer intervals were of the histiocytic (reticulosarcoma) type. 
